The company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps.
| Status | Suspended |
| Technology type | Medicine |
| Decision | Selected |
| Reason for decision | Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources |
| Process | STA Standard |
| ID number | 6172 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 26 March 2024 | Suspended. The company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps. |
| 28 February 2024 | Awaiting development. The National Institute for Health and Care Excellence (NICE) has been asked to conduct an appraisal of pemigatinib for treating myeloproliferative neoplasms with an FGFR1 rearrangement ID6172. We have recently invited stakeholders to respond to a written consultation on the draft scope and to attend a scoping workshop for this appraisal. Following an update from the company that market pemigatinib, NICE will not be progressing with the scoping exercise. Due to this, the workshop arranged for Wednesday 13 March 2024 has been cancelled. Please accept our apologies for any inconvenience. |
| 24 January 2024 - 21 February 2024 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6172 |
| 24 January 2024 | In progress. Scoping commencing |
| 11 August 2022 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual